Gregory Moeck

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1354348/publications.pdf

Version: 2024-02-01

55	2,026	304743	233421
papers	citations	22 h-index	45 g-index

55	55	55	1756
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine, 2014, 370, 2180-2190.	27.0	244
2	Antimicrobial drug discovery through bacteriophage genomics. Nature Biotechnology, 2004, 22, 185-191.	17.5	210
3	Single-Dose Oritavancin Versus 7â€“10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study. Clinical Infectious Diseases, 2015, 60, 254-262.	5.8	179
4	Oritavancin Kills Stationary-Phase and BiofilmStaphylococcus aureusCells In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 918-925.	3.2	152
5	Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. Journal of Antimicrobial Chemotherapy, 2009, 63, 1191-1199.	3.0	119
6	Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing. Antimicrobial Agents and Chemotherapy, 2010, 54, 5369-5371.	3.2	92
7	Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing. Antimicrobial Agents and Chemotherapy, 2008, 52, 1597-1603.	3.2	87
8	Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis. Journal of Medicinal Chemistry, 2008, 51, 6955-6969.	6.4	67
9	Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2008, 52, 3820-3822.	3.2	63
10	Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2009, 53, 4762-4771.	3.2	60
11	Genome Annotation and Intraviral Interactome for the Streptococcus pneumoniae Virulent Phage Dp-1. Journal of Bacteriology, 2011, 193, 551-562.	2.2	50
12	Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1286-1290.	2.2	47
13	Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. Bioorganic and Medicinal Chemistry, 2008, 16, 9217-9229.	3.0	40
14	A new class of small molecule RNA polymerase inhibitors with activity against Rifampicin-resistant Staphylococcus aureus1. Bioorganic and Medicinal Chemistry, 2006, 14, 5812-5832.	3.0	38
15	Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. Journal of Antimicrobial Chemotherapy, 2009, 64, 868-870.	3.0	34
16	Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 205-211.	3.2	34
17	Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Antimicrobial Agents and Chemotherapy, 2009, 53, 800-804.	3.2	29
18	Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Molecular Microbiology, 2006, 62, 1132-1143.	2.5	28

#	Article	IF	Citations
19	Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents, 2016, 48, 528-534.	2.5	28
20	Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2017, 87, 121-128.	1.8	27
21	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1355-1359.	2.2	25
22	Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis. ChemMedChem, 2008, 3, 1863-1868.	3.2	22
23	In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011â€“2014. International Journal of Antimicrobial Agents, 2015, 46, 674-681.	2.5	22
24	Inhibition of Transcription in Staphylococcus aureus by a Primary Sigma Factor-Binding Polypeptide from Phage G1. Journal of Bacteriology, 2009, 191, 3763-3771.	2.2	21
25	Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
26	Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide. Antimicrobial Agents and Chemotherapy, 2015, 59, 2405-2409.	3.2	18
27	Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. Antimicrobial Agents and Chemotherapy, 2016, 60, 4342-4345.	3.2	18
28	Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci. Antimicrobial Agents and Chemotherapy, 2009, 53, 2687-2689.	3.2	17
29	Assessment of Oritavancin Serum Protein Binding across Species. Antimicrobial Agents and Chemotherapy, 2010, 54, 3481-3483.	3.2	17
30	Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci. Journal of Antimicrobial Chemotherapy, 2017, 72, 622-624.	3.0	16
31	A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program. Open Forum Infectious Diseases, 2018, 5, ofy051.	0.9	16
32	Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagnostic Microbiology and Infectious Disease, 2008, 62, 92-95.	1.8	14
33	Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. Journal of Antimicrobial Chemotherapy, 2012, 67, 2919-2926.	3.0	14
34	Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. Antimicrobial Agents and Chemotherapy, 2016, 60, 3174-3177.	3.2	14
35	Timeâ€“kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes. International Journal of Antimicrobial Agents, 2009, 34, 550-554.	2.5	13
36	Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus. International Journal of Antimicrobial Agents, 2012, 39, 159-162.	2.5	13

#	Article	IF	Citations
37	In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. International Journal of Antimicrobial Agents, 2014, 44, 65-68.	2.5	12
38	Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates. International Journal of Antimicrobial Agents, 2010, 35, 93-94.	2.5	11
39	Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
40	Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	11
41	In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 349-356.	1.8	10
42	Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005â€“2008. International Journal of Antimicrobial Agents, 2010, 36, 474-476.	2.5	9
43	In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci. Diagnostic Microbiology and Infectious Disease, 2017, 89, 168-171.	1.8	9
44	Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci. International Journal of Antimicrobial Agents, 2012, 40, 562-563.	2.5	8
45	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	8
46	Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics. Current Protocols in Microbiology, 2010, 16, Unit17.1.	6.5	6
47	Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 2009, 65, 207-210.	1.8	5
48	Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). International Journal of Antimicrobial Agents, 2013, 41, 397-398.	2.5	5
49	Assessment of the potential for oritavancin MIC changes among Staphylococcus aureus nasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections. Journal of Global Antimicrobial Resistance, 2017, 9, 8-9.	2.2	5
50	Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital. International Journal of Antimicrobial Agents, 2009, 34, 540-543.	2.5	4
51	Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci. Journal of Global Antimicrobial Resistance, 2017, 9, 85-86.	2.2	3
52	Interference of Oritavancin on Coagulation Tests as Assessed In Vitro and in a Phase 1 Study of Normal Healthy Volunteers. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
53	Antibacterial Activity of Oritavancin and Daptomycin Against Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
54	Competition of bacteriophage polypeptides with native replicase proteins for binding to the DNA sliding clamp reveals a novel mechanism for DNA replication arrest in Staphylococcus aureus. Molecular Microbiology, 2006, 62, 1764-1764.	2.5	0

#	Article	IF	Citations
55	Drug Development for Drug-Resistant Pathogens. , 2017, , 45-57.		0